Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells

Background LOX-1, a lectin-like receptor on endothelial cells, facilitates the uptake of oxidized low-density lipoprotein (oxLDL). Expression of LOX-1 is involved in the pathobiological effects of oxLDL in endothelial cells, including reactive oxygen species (ROS) generation, suppression of endothel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of vascular surgery 2010-11, Vol.52 (5), p.1290-1300
Hauptverfasser: Lee, Wen-Jane, PhD, Ou, Hsiu-Chung, PhD, Hsu, Wen-Cheng, MD, Chou, Min-Min, MD, Tseng, Jenn-Jhy, MD, PhD, Hsu, Shih-Lan, PhD, Tsai, Kun-Ling, MS, Sheu, Wayne Huey-Herng, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1300
container_issue 5
container_start_page 1290
container_title Journal of vascular surgery
container_volume 52
creator Lee, Wen-Jane, PhD
Ou, Hsiu-Chung, PhD
Hsu, Wen-Cheng, MD
Chou, Min-Min, MD
Tseng, Jenn-Jhy, MD, PhD
Hsu, Shih-Lan, PhD
Tsai, Kun-Ling, MS
Sheu, Wayne Huey-Herng, MD, PhD
description Background LOX-1, a lectin-like receptor on endothelial cells, facilitates the uptake of oxidized low-density lipoprotein (oxLDL). Expression of LOX-1 is involved in the pathobiological effects of oxLDL in endothelial cells, including reactive oxygen species (ROS) generation, suppression of endothelial nitric oxide synthase (eNOS) activity, and leukocytic adhesion. Moderate consumption of phenolic-enriched food may have a protective effect against the development of atherosclerosis via the antioxidant capacity of phenolic compounds at the endothelial level. In this study, we determined whether ellagic acid, a polyphenolic compound widely distributed in fruits and nuts, protects against oxLDL-induced endothelial dysfunction by modulating the LOX-1-mediated signaling pathway. Methods Human umbilical vein endothelial cells (HUVECs) were pretreated with ellagic acid at doses of 5, 10, 15, and 20 μM for 2 hours and then incubated with oxLDL (150 μg/mL) for an additional 24 hours. Results LOX-1 protein expression was markedly lower after exposure to oxLDL in HUVECs pretreated with ellagic acid or diphenyleneiodonium, a well-known inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, than in HUVECs exposed to oxLDL alone, suggesting that ellagic acid deactivates NADPH oxidase. We also found that oxLDL activated the membrane assembly of p47phox , Rac1, gp91 and p22phox , and the subsequent induction of ROS generation; however, ROS generation was markedly suppressed in cells pretreated with ellagic acid or anti-LOX-1 monoclonal antibody. In addition, oxLDL down-regulated eNOS and up-regulated inducible NO synthase (iNOS), thereby augmenting the formation of NO and protein nitrosylation. Furthermore, oxLDL induced the phosphorylation of p38 mitogen-activated protein kinase, activated the NF-κB-mediated inflammatory signaling molecules interleukin-(IL) 6 and IL-8 and the adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin, and stimulated the adherence of THP-1 (a human acute monocytic leukemia cell line) to HUVECs. Pretreatment with ellagic acid, however, exerted significant cytoprotective effects in all events. Conclusion Findings from this study may provide insight into a possible molecular mechanism by which ellagic acid inhibits LOX-1-induced endothelial dysfunction. Our data indicate that ellagic acid exerts its protective effects by inhibiting NADPH oxidase-induced overproduction of superox
doi_str_mv 10.1016/j.jvs.2010.04.085
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_762684916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0741521410013480</els_id><sourcerecordid>762684916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-4c4dc8075aebea7311376777e71ef773d699d47bb3f7d89c8dc76d8e508a244f3</originalsourceid><addsrcrecordid>eNp9kl-L1DAUxYMo7rj6AXyRvIgvdkyatEkRBFnXPzAw4Cr4FtLkdic1TcekXXb89KY7o4IPPoUTzjn38uMi9JSSNSW0ftWv-5u0LknWhK-JrO6hFSWNKGpJmvtoRQSnRVVSfoYepdQTQmklxUN0VpK6KUVTrdDh0nt97QzWxlnsws61bkp4vHXW_QSLN-82xQDW6WkR228FxXC7j5CSG8NL_Hl7ha8hQNTTndZhKem8Hoa7nyzwbh50wBDsOO3AO-2xAe_TY_Sg0z7Bk9N7jr6-v_xy8bHYbD98uni7KUzF66nghlsjiag0tKAFo5SJWggBgkInBLN101gu2pZ1wsrGSGtEbSVUROqS846doxfH3n0cf8yQJjW4tGygA4xzUqIua8kbWmcnPTpNHFOK0Kl9dIOOB0WJWoCrXmXgagGuCFcZeM48O7XPbeb0J_GbcDY8Pxl0Mtp3UQfj0l8f41XD2DL89dEHmcWNg6iScRBMZh_BTMqO7r9rvPknbbwLLg_8DgdI_TjHkCErqlKpiLpaLmM5DJpvgnFJ2C-DsbMZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>762684916</pqid></control><display><type>article</type><title>Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lee, Wen-Jane, PhD ; Ou, Hsiu-Chung, PhD ; Hsu, Wen-Cheng, MD ; Chou, Min-Min, MD ; Tseng, Jenn-Jhy, MD, PhD ; Hsu, Shih-Lan, PhD ; Tsai, Kun-Ling, MS ; Sheu, Wayne Huey-Herng, MD, PhD</creator><creatorcontrib>Lee, Wen-Jane, PhD ; Ou, Hsiu-Chung, PhD ; Hsu, Wen-Cheng, MD ; Chou, Min-Min, MD ; Tseng, Jenn-Jhy, MD, PhD ; Hsu, Shih-Lan, PhD ; Tsai, Kun-Ling, MS ; Sheu, Wayne Huey-Herng, MD, PhD</creatorcontrib><description>Background LOX-1, a lectin-like receptor on endothelial cells, facilitates the uptake of oxidized low-density lipoprotein (oxLDL). Expression of LOX-1 is involved in the pathobiological effects of oxLDL in endothelial cells, including reactive oxygen species (ROS) generation, suppression of endothelial nitric oxide synthase (eNOS) activity, and leukocytic adhesion. Moderate consumption of phenolic-enriched food may have a protective effect against the development of atherosclerosis via the antioxidant capacity of phenolic compounds at the endothelial level. In this study, we determined whether ellagic acid, a polyphenolic compound widely distributed in fruits and nuts, protects against oxLDL-induced endothelial dysfunction by modulating the LOX-1-mediated signaling pathway. Methods Human umbilical vein endothelial cells (HUVECs) were pretreated with ellagic acid at doses of 5, 10, 15, and 20 μM for 2 hours and then incubated with oxLDL (150 μg/mL) for an additional 24 hours. Results LOX-1 protein expression was markedly lower after exposure to oxLDL in HUVECs pretreated with ellagic acid or diphenyleneiodonium, a well-known inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, than in HUVECs exposed to oxLDL alone, suggesting that ellagic acid deactivates NADPH oxidase. We also found that oxLDL activated the membrane assembly of p47phox , Rac1, gp91 and p22phox , and the subsequent induction of ROS generation; however, ROS generation was markedly suppressed in cells pretreated with ellagic acid or anti-LOX-1 monoclonal antibody. In addition, oxLDL down-regulated eNOS and up-regulated inducible NO synthase (iNOS), thereby augmenting the formation of NO and protein nitrosylation. Furthermore, oxLDL induced the phosphorylation of p38 mitogen-activated protein kinase, activated the NF-κB-mediated inflammatory signaling molecules interleukin-(IL) 6 and IL-8 and the adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin, and stimulated the adherence of THP-1 (a human acute monocytic leukemia cell line) to HUVECs. Pretreatment with ellagic acid, however, exerted significant cytoprotective effects in all events. Conclusion Findings from this study may provide insight into a possible molecular mechanism by which ellagic acid inhibits LOX-1-induced endothelial dysfunction. Our data indicate that ellagic acid exerts its protective effects by inhibiting NADPH oxidase-induced overproduction of superoxide, suppressing the release of NO by down-regulating iNOS, enhancing cellular antioxidant defenses, and attenuating oxLDL-induced LOX-1 up-regulation and eNOS down-regulation.</description><identifier>ISSN: 0741-5214</identifier><identifier>EISSN: 1097-6809</identifier><identifier>DOI: 10.1016/j.jvs.2010.04.085</identifier><identifier>PMID: 20692795</identifier><identifier>CODEN: JVSUES</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Anti-Inflammatory Agents - pharmacology ; Antioxidants - pharmacology ; Biological and medical sciences ; Cardiovascular system ; Cell Adhesion Molecules - metabolism ; Cells, Cultured ; Dose-Response Relationship, Drug ; Down-Regulation ; Ellagic Acid - pharmacology ; Endothelial Cells - drug effects ; Endothelial Cells - immunology ; Endothelial Cells - metabolism ; Enzyme Inhibitors - pharmacology ; Humans ; Inflammation - immunology ; Inflammation - metabolism ; Inflammation - prevention &amp; control ; Inflammation Mediators - metabolism ; Interleukin-6 - metabolism ; Interleukin-8 - metabolism ; Investigative techniques, diagnostic techniques (general aspects) ; Lipoproteins, LDL - metabolism ; Medical sciences ; NADPH Oxidases - antagonists &amp; inhibitors ; NADPH Oxidases - metabolism ; NF-kappa B - metabolism ; Nitric Oxide - metabolism ; Nitric Oxide Synthase Type II - metabolism ; Nitric Oxide Synthase Type III - metabolism ; Onium Compounds - pharmacology ; p38 Mitogen-Activated Protein Kinases - metabolism ; Phosphorylation ; Radionuclide investigations ; Reactive Oxygen Species - metabolism ; Scavenger Receptors, Class E - metabolism ; Signal Transduction - drug effects ; Superoxides - metabolism ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</subject><ispartof>Journal of vascular surgery, 2010-11, Vol.52 (5), p.1290-1300</ispartof><rights>Society for Vascular Surgery</rights><rights>2010 Society for Vascular Surgery</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-4c4dc8075aebea7311376777e71ef773d699d47bb3f7d89c8dc76d8e508a244f3</citedby><cites>FETCH-LOGICAL-c546t-4c4dc8075aebea7311376777e71ef773d699d47bb3f7d89c8dc76d8e508a244f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0741521410013480$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23459336$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20692795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Wen-Jane, PhD</creatorcontrib><creatorcontrib>Ou, Hsiu-Chung, PhD</creatorcontrib><creatorcontrib>Hsu, Wen-Cheng, MD</creatorcontrib><creatorcontrib>Chou, Min-Min, MD</creatorcontrib><creatorcontrib>Tseng, Jenn-Jhy, MD, PhD</creatorcontrib><creatorcontrib>Hsu, Shih-Lan, PhD</creatorcontrib><creatorcontrib>Tsai, Kun-Ling, MS</creatorcontrib><creatorcontrib>Sheu, Wayne Huey-Herng, MD, PhD</creatorcontrib><title>Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells</title><title>Journal of vascular surgery</title><addtitle>J Vasc Surg</addtitle><description>Background LOX-1, a lectin-like receptor on endothelial cells, facilitates the uptake of oxidized low-density lipoprotein (oxLDL). Expression of LOX-1 is involved in the pathobiological effects of oxLDL in endothelial cells, including reactive oxygen species (ROS) generation, suppression of endothelial nitric oxide synthase (eNOS) activity, and leukocytic adhesion. Moderate consumption of phenolic-enriched food may have a protective effect against the development of atherosclerosis via the antioxidant capacity of phenolic compounds at the endothelial level. In this study, we determined whether ellagic acid, a polyphenolic compound widely distributed in fruits and nuts, protects against oxLDL-induced endothelial dysfunction by modulating the LOX-1-mediated signaling pathway. Methods Human umbilical vein endothelial cells (HUVECs) were pretreated with ellagic acid at doses of 5, 10, 15, and 20 μM for 2 hours and then incubated with oxLDL (150 μg/mL) for an additional 24 hours. Results LOX-1 protein expression was markedly lower after exposure to oxLDL in HUVECs pretreated with ellagic acid or diphenyleneiodonium, a well-known inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, than in HUVECs exposed to oxLDL alone, suggesting that ellagic acid deactivates NADPH oxidase. We also found that oxLDL activated the membrane assembly of p47phox , Rac1, gp91 and p22phox , and the subsequent induction of ROS generation; however, ROS generation was markedly suppressed in cells pretreated with ellagic acid or anti-LOX-1 monoclonal antibody. In addition, oxLDL down-regulated eNOS and up-regulated inducible NO synthase (iNOS), thereby augmenting the formation of NO and protein nitrosylation. Furthermore, oxLDL induced the phosphorylation of p38 mitogen-activated protein kinase, activated the NF-κB-mediated inflammatory signaling molecules interleukin-(IL) 6 and IL-8 and the adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin, and stimulated the adherence of THP-1 (a human acute monocytic leukemia cell line) to HUVECs. Pretreatment with ellagic acid, however, exerted significant cytoprotective effects in all events. Conclusion Findings from this study may provide insight into a possible molecular mechanism by which ellagic acid inhibits LOX-1-induced endothelial dysfunction. Our data indicate that ellagic acid exerts its protective effects by inhibiting NADPH oxidase-induced overproduction of superoxide, suppressing the release of NO by down-regulating iNOS, enhancing cellular antioxidant defenses, and attenuating oxLDL-induced LOX-1 up-regulation and eNOS down-regulation.</description><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Antioxidants - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Cell Adhesion Molecules - metabolism</subject><subject>Cells, Cultured</subject><subject>Dose-Response Relationship, Drug</subject><subject>Down-Regulation</subject><subject>Ellagic Acid - pharmacology</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - immunology</subject><subject>Endothelial Cells - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Inflammation - prevention &amp; control</subject><subject>Inflammation Mediators - metabolism</subject><subject>Interleukin-6 - metabolism</subject><subject>Interleukin-8 - metabolism</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Lipoproteins, LDL - metabolism</subject><subject>Medical sciences</subject><subject>NADPH Oxidases - antagonists &amp; inhibitors</subject><subject>NADPH Oxidases - metabolism</subject><subject>NF-kappa B - metabolism</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase Type II - metabolism</subject><subject>Nitric Oxide Synthase Type III - metabolism</subject><subject>Onium Compounds - pharmacology</subject><subject>p38 Mitogen-Activated Protein Kinases - metabolism</subject><subject>Phosphorylation</subject><subject>Radionuclide investigations</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Scavenger Receptors, Class E - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Superoxides - metabolism</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</subject><issn>0741-5214</issn><issn>1097-6809</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kl-L1DAUxYMo7rj6AXyRvIgvdkyatEkRBFnXPzAw4Cr4FtLkdic1TcekXXb89KY7o4IPPoUTzjn38uMi9JSSNSW0ftWv-5u0LknWhK-JrO6hFSWNKGpJmvtoRQSnRVVSfoYepdQTQmklxUN0VpK6KUVTrdDh0nt97QzWxlnsws61bkp4vHXW_QSLN-82xQDW6WkR228FxXC7j5CSG8NL_Hl7ha8hQNTTndZhKem8Hoa7nyzwbh50wBDsOO3AO-2xAe_TY_Sg0z7Bk9N7jr6-v_xy8bHYbD98uni7KUzF66nghlsjiag0tKAFo5SJWggBgkInBLN101gu2pZ1wsrGSGtEbSVUROqS846doxfH3n0cf8yQJjW4tGygA4xzUqIua8kbWmcnPTpNHFOK0Kl9dIOOB0WJWoCrXmXgagGuCFcZeM48O7XPbeb0J_GbcDY8Pxl0Mtp3UQfj0l8f41XD2DL89dEHmcWNg6iScRBMZh_BTMqO7r9rvPknbbwLLg_8DgdI_TjHkCErqlKpiLpaLmM5DJpvgnFJ2C-DsbMZ</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>Lee, Wen-Jane, PhD</creator><creator>Ou, Hsiu-Chung, PhD</creator><creator>Hsu, Wen-Cheng, MD</creator><creator>Chou, Min-Min, MD</creator><creator>Tseng, Jenn-Jhy, MD, PhD</creator><creator>Hsu, Shih-Lan, PhD</creator><creator>Tsai, Kun-Ling, MS</creator><creator>Sheu, Wayne Huey-Herng, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20101101</creationdate><title>Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells</title><author>Lee, Wen-Jane, PhD ; Ou, Hsiu-Chung, PhD ; Hsu, Wen-Cheng, MD ; Chou, Min-Min, MD ; Tseng, Jenn-Jhy, MD, PhD ; Hsu, Shih-Lan, PhD ; Tsai, Kun-Ling, MS ; Sheu, Wayne Huey-Herng, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-4c4dc8075aebea7311376777e71ef773d699d47bb3f7d89c8dc76d8e508a244f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Antioxidants - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Cell Adhesion Molecules - metabolism</topic><topic>Cells, Cultured</topic><topic>Dose-Response Relationship, Drug</topic><topic>Down-Regulation</topic><topic>Ellagic Acid - pharmacology</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - immunology</topic><topic>Endothelial Cells - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Inflammation - prevention &amp; control</topic><topic>Inflammation Mediators - metabolism</topic><topic>Interleukin-6 - metabolism</topic><topic>Interleukin-8 - metabolism</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Lipoproteins, LDL - metabolism</topic><topic>Medical sciences</topic><topic>NADPH Oxidases - antagonists &amp; inhibitors</topic><topic>NADPH Oxidases - metabolism</topic><topic>NF-kappa B - metabolism</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase Type II - metabolism</topic><topic>Nitric Oxide Synthase Type III - metabolism</topic><topic>Onium Compounds - pharmacology</topic><topic>p38 Mitogen-Activated Protein Kinases - metabolism</topic><topic>Phosphorylation</topic><topic>Radionuclide investigations</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Scavenger Receptors, Class E - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Superoxides - metabolism</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Wen-Jane, PhD</creatorcontrib><creatorcontrib>Ou, Hsiu-Chung, PhD</creatorcontrib><creatorcontrib>Hsu, Wen-Cheng, MD</creatorcontrib><creatorcontrib>Chou, Min-Min, MD</creatorcontrib><creatorcontrib>Tseng, Jenn-Jhy, MD, PhD</creatorcontrib><creatorcontrib>Hsu, Shih-Lan, PhD</creatorcontrib><creatorcontrib>Tsai, Kun-Ling, MS</creatorcontrib><creatorcontrib>Sheu, Wayne Huey-Herng, MD, PhD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of vascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Wen-Jane, PhD</au><au>Ou, Hsiu-Chung, PhD</au><au>Hsu, Wen-Cheng, MD</au><au>Chou, Min-Min, MD</au><au>Tseng, Jenn-Jhy, MD, PhD</au><au>Hsu, Shih-Lan, PhD</au><au>Tsai, Kun-Ling, MS</au><au>Sheu, Wayne Huey-Herng, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells</atitle><jtitle>Journal of vascular surgery</jtitle><addtitle>J Vasc Surg</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>52</volume><issue>5</issue><spage>1290</spage><epage>1300</epage><pages>1290-1300</pages><issn>0741-5214</issn><eissn>1097-6809</eissn><coden>JVSUES</coden><abstract>Background LOX-1, a lectin-like receptor on endothelial cells, facilitates the uptake of oxidized low-density lipoprotein (oxLDL). Expression of LOX-1 is involved in the pathobiological effects of oxLDL in endothelial cells, including reactive oxygen species (ROS) generation, suppression of endothelial nitric oxide synthase (eNOS) activity, and leukocytic adhesion. Moderate consumption of phenolic-enriched food may have a protective effect against the development of atherosclerosis via the antioxidant capacity of phenolic compounds at the endothelial level. In this study, we determined whether ellagic acid, a polyphenolic compound widely distributed in fruits and nuts, protects against oxLDL-induced endothelial dysfunction by modulating the LOX-1-mediated signaling pathway. Methods Human umbilical vein endothelial cells (HUVECs) were pretreated with ellagic acid at doses of 5, 10, 15, and 20 μM for 2 hours and then incubated with oxLDL (150 μg/mL) for an additional 24 hours. Results LOX-1 protein expression was markedly lower after exposure to oxLDL in HUVECs pretreated with ellagic acid or diphenyleneiodonium, a well-known inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, than in HUVECs exposed to oxLDL alone, suggesting that ellagic acid deactivates NADPH oxidase. We also found that oxLDL activated the membrane assembly of p47phox , Rac1, gp91 and p22phox , and the subsequent induction of ROS generation; however, ROS generation was markedly suppressed in cells pretreated with ellagic acid or anti-LOX-1 monoclonal antibody. In addition, oxLDL down-regulated eNOS and up-regulated inducible NO synthase (iNOS), thereby augmenting the formation of NO and protein nitrosylation. Furthermore, oxLDL induced the phosphorylation of p38 mitogen-activated protein kinase, activated the NF-κB-mediated inflammatory signaling molecules interleukin-(IL) 6 and IL-8 and the adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin, and stimulated the adherence of THP-1 (a human acute monocytic leukemia cell line) to HUVECs. Pretreatment with ellagic acid, however, exerted significant cytoprotective effects in all events. Conclusion Findings from this study may provide insight into a possible molecular mechanism by which ellagic acid inhibits LOX-1-induced endothelial dysfunction. Our data indicate that ellagic acid exerts its protective effects by inhibiting NADPH oxidase-induced overproduction of superoxide, suppressing the release of NO by down-regulating iNOS, enhancing cellular antioxidant defenses, and attenuating oxLDL-induced LOX-1 up-regulation and eNOS down-regulation.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>20692795</pmid><doi>10.1016/j.jvs.2010.04.085</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0741-5214
ispartof Journal of vascular surgery, 2010-11, Vol.52 (5), p.1290-1300
issn 0741-5214
1097-6809
language eng
recordid cdi_proquest_miscellaneous_762684916
source MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Anti-Inflammatory Agents - pharmacology
Antioxidants - pharmacology
Biological and medical sciences
Cardiovascular system
Cell Adhesion Molecules - metabolism
Cells, Cultured
Dose-Response Relationship, Drug
Down-Regulation
Ellagic Acid - pharmacology
Endothelial Cells - drug effects
Endothelial Cells - immunology
Endothelial Cells - metabolism
Enzyme Inhibitors - pharmacology
Humans
Inflammation - immunology
Inflammation - metabolism
Inflammation - prevention & control
Inflammation Mediators - metabolism
Interleukin-6 - metabolism
Interleukin-8 - metabolism
Investigative techniques, diagnostic techniques (general aspects)
Lipoproteins, LDL - metabolism
Medical sciences
NADPH Oxidases - antagonists & inhibitors
NADPH Oxidases - metabolism
NF-kappa B - metabolism
Nitric Oxide - metabolism
Nitric Oxide Synthase Type II - metabolism
Nitric Oxide Synthase Type III - metabolism
Onium Compounds - pharmacology
p38 Mitogen-Activated Protein Kinases - metabolism
Phosphorylation
Radionuclide investigations
Reactive Oxygen Species - metabolism
Scavenger Receptors, Class E - metabolism
Signal Transduction - drug effects
Superoxides - metabolism
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels
title Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T23%3A03%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ellagic%20acid%20inhibits%20oxidized%20LDL-mediated%20LOX-1%20expression,%20ROS%20generation,%20and%20inflammation%20in%20human%20endothelial%20cells&rft.jtitle=Journal%20of%20vascular%20surgery&rft.au=Lee,%20Wen-Jane,%20PhD&rft.date=2010-11-01&rft.volume=52&rft.issue=5&rft.spage=1290&rft.epage=1300&rft.pages=1290-1300&rft.issn=0741-5214&rft.eissn=1097-6809&rft.coden=JVSUES&rft_id=info:doi/10.1016/j.jvs.2010.04.085&rft_dat=%3Cproquest_cross%3E762684916%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=762684916&rft_id=info:pmid/20692795&rft_els_id=S0741521410013480&rfr_iscdi=true